News

FDA MedWatch: Fresenius Medical Care Recalls Some Hemodialysis Machines for Potential Exposure to Toxic Compounds

Fresenius Medical Care Recalls Some Hemodialysis Machines for Potential Exposure to Toxic Compounds

KCER Release Date: October 27, 2023

To: KCER Distribution list- including ESRD Network EDs and QIDs

FDA MedWatch: Exela Pharma Sciences, LLC Issues Voluntary Nationwide Recall of 8.4% Sodium Bicarbonate Injection, USP, 50 mEq/50 mL, Midazolam in 0.8% Sodium Chloride Injection 100 mg/100 mL, and ELCYS (cysteine hydrochloride Injection), USP 500 mg/10 mL

FDA MedWatch

FDA MedWatch: 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP by Hospira: Recall - Due to the Potential for Presence of Glass Particulate Matter

FDA MedWatch

FDA MedWatch: Novartis Issues Voluntary Nationwide Recall of One Lot of Sandimmune® Oral Solution (Cyclosporine Oral Solution, USP), 100 mg/mL Due to Crystallization

From KCER (Kidney Community Emergency Response)

https://www.hhs.gov/about/news/2023/02/09/fact-sheet-covid-19-public-health-emergency-transition-roadmap.html

FDA Safety Communication - Alcohol Antiseptic Recall

FDA MedWatch

Update: Potential Risk of Exposure to Toxic Compounds When Using Hemodialysis and Peritoneal Dialysis Systems – Letter to Health Care Providers

KCER Release Date: March 7, 2023

To: KCER Distribution list- including ESRD Network EDs and QIDs

REMINDER: Q4 2022 Dialysis Event data to NHSN by March 31

Outpatient hemodialysis facilities participating in the Centers for Medicare and Medicaid Services (CMS) End-Stage Renal Disease (ESRD) Quality Incentive Program (QIP) must submit their Q4 2022 Dialysis Event data to NHSN

CMS Waivers, Flexibilities, and the Transition Forward from the COVID-19 Public Health Emergency

What Do I Need to Know?

CMS Waivers, Flexibilities, and the Transition Forward from the COVID-19 Public Health Emergency

Pages